Loading
Life sciences · Journal article
Nutrients · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Its prevalence is constantly increasing, particularly among obese individuals. Lifestyle modifications remain the first-line intervention for the management and treatment of MASLD. The most widely recommended dietary regime for MASLD is the Mediterranean Diet (MedDiet). Despite its countless benefits, this dietary regimen is difficult to follow in some cases. This study aimed to assess the effects of an 8-week Very Low-Calorie Ketogenic Diet (VLCKD) in obese patients with MASLD. Methods: The study included 55 obese adults aged 18–64 years, recruited from the Center of Nutrition for Obesity and Metabolic Diseases, National Institute of Gastroenterology “Saverio de Bellis” Research Hospital (Castellana Grotte, Bari, Italy). Anthropometry, body composition (BIA), liver status (FibroScan®), serum biochemistry and circulating biomarkers of adipose dysfunction were assessed at baseline (T0) and post-intervention (T1). Results: Significant improvements in liver steatosis (CAP p < 0.0001), liver stiffness (p = 0.0005), anthropometric parameters (waist p < 0.0001), and body composition (FM p <0.0001) were observed. A significant reduction in leptin levels and an increase in sex hormone-binding globulin (SHBG p < 0.0001) were also observed. Conclusions: In this uncontrolled pre-post analysis, the 8-week VLCKD intervention was associated with improvements in hepatic steatosis, body weight, and fat mass, and selected circulating biomarkers of adipose tissue dysfunction in adults with obesity and MASLD.